<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121260">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524133</url>
  </required_header>
  <id_info>
    <org_study_id>PROGrESS</org_study_id>
    <nct_id>NCT01524133</nct_id>
  </id_info>
  <brief_title>PROlonGed ExpoSure Sertraline</brief_title>
  <acronym>PROGrESS</acronym>
  <official_title>Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Ann Arbor Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Ann Arbor Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current research study aims to compare the effectiveness of two proven treatments for
      posttraumatic stress disorder (PTSD): Prolonged Exposure (PE), sertraline, and their
      combination. In addition, the investigators are examining predictors of response to these
      two treatments and how PTSD symptoms, thoughts, and biological factors may be changed by
      such treatments. Biological mechanisms of change are also examined including emotion
      processing and regulation in fMRI, HPA axis function, and genetics and genomics. In
      addition, the investigators will examine acceptability of each treatment and reasons for
      ending treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posttraumatic stress disorder (PTSD) symptoms as measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic stress disorder (PTSD) related psychopathology, including depression, alcohol and substance abuse, and general anxiety</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">441</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline + enhanced medication management (SERT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 weeks of sertraline + enhanced medication management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolonged Exposure + sertraline (PE/SERT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolonged Exposure + placebo (PE/PLB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
    <arm_group_label>Sertraline + enhanced medication management (SERT)</arm_group_label>
    <arm_group_label>Prolonged Exposure + sertraline (PE/SERT)</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prolonged Exposure Therapy</intervention_name>
    <description>up to 13 sessions of prolonged exposure</description>
    <arm_group_label>Prolonged Exposure + sertraline (PE/SERT)</arm_group_label>
    <arm_group_label>Prolonged Exposure + placebo (PE/PLB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is an Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn
             (OEF/OIF/OND) combat veteran with chronic posttraumatic stress disorder (PTSD) or
             significant PTSD symptoms (Clinician Administered Posttraumatic Stress Disorder Scale
             [CAPS] &gt;= 50) of at least 3 months duration

        Exclusion Criteria:

          -  Current, imminent risk of suicide (as indicated on C-SSRS)

          -  Active psychosis

          -  Alcohol or substance dependence in the past 8 weeks

          -  Unable to attend regular appointments

          -  Prior intolerance or failure of adequate trial of prolonged exposure (PE) or
             sertraline (SERT) (defined as at least 2 months of SERT at least 100mg/day)

          -  Medical illness likely to result in hospitalization or for which treatments are
             contraindicated (based on lab results, medical history and physical exam)

          -  Serious cognitive impairment (as evidenced by cognitive impairment felt likely to
             interfere with the ability to participate meaningfully in the study)

          -  Concurrent antidepressants or antipsychotics

          -  Pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Rauch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center/Savannah Primary Care Clinic</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Ann Arbor Healthcare System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 16, 2016</lastchanged_date>
  <firstreceived_date>January 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atlanta VA Medical Center</investigator_affiliation>
    <investigator_full_name>Sheila Rauch</investigator_full_name>
    <investigator_title>Clinical Director of Wounded Warrior Project and Associate Professor at Emory University, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>combat-related PTSD</keyword>
  <keyword>Posttraumatic stress disorder</keyword>
  <keyword>prolonged exposure therapy</keyword>
  <keyword>sertraline</keyword>
  <keyword>military</keyword>
  <keyword>veterans</keyword>
  <keyword>VA hospital</keyword>
  <keyword>mental illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
